Literature DB >> 32156708

Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease.

Raul Castellanos-Moreira1, Sebastian Cruz Rodríguez-García1, Maria Jose Gomara2, Virginia Ruiz-Esquide1, Andrea Cuervo1, Ivette Casafont-Solé3, Julio Ramírez1, Susana Holgado3, Jose A Gómez-Puerta1, Juan D Cañete1, Isabel Haro2, Raimon Sanmarti4.   

Abstract

OBJECTIVE: To analyse the association between anti-carbamylated protein antibodies (Anti-CarP) and interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients.
METHODS: Cross-sectional study including RA patients fulfilling the 2010 ACR/EULAR criteria. The main population comprised two groups: (1) RA patients diagnosed with RA-ILD (RA-ILD group); (2) RA patients without ILD (non-ILD RA group). Non-ILD RA patients in whom ILD was suspected underwent a diagnostic work-up and, if ILD was diagnosed, were switched to the RA-ILD group. ILD was diagnosed by high-resolution computed tomography and confirmed by a multidisciplinary committee. An independent replication sample was also obtained. Three Anti-CarP IgG autoantibodies against fetal calf serum (Anti-FCS), fibrinogen (Anti-Fib) and chimeric fibrine/filagrine homocitrullinated peptide (Anti-CFFHP) and one Anti-CarP IgA against FCS (Anti-FCS-IgA) were determined by home-made ELISA. Associations between Anti-CarP and ILD were analysed using multivariable logistic regression adjusted by smoking, sex, age, RA disease duration, rheumatoid factor and anticitrullinated protein antibodies.
RESULTS: We enrolled 179 patients: 37 (21%) were finally diagnosed with RA-ILD. Anti-CarP specificities were more frequent in RA-ILD patients (Anti-FCS 70% vs 43%; Anti-Fib 73% vs 51%; Anti-CFFHP 38% vs 19%; Anti-CarP-IgA 51% vs 20%, p<0.05 for all comparisons). Serum titers of Anti-CarP were significantly higher in RA-ILD patients. Anti-CarP specificities showed a robust effect towards increasing the odds of ILD in the multivariate analysis (Anti-FCS (OR: 3.42; 95% CI: 1.13 to 10.40), Anti-Fib (OR: 2.85; 95% CI: 0.83 to 9.70), Anti-CFFHP (OR: 3.11; 95% CI: 1.06 to 9.14) and Anti-FCS-IgA (OR: 4.30; 95% CI: 1.41 to 13.04)). Similar findings were observed in the replication sample.
CONCLUSIONS: Anti-CarP were strongly associated with ILD. The role of homocitrullination in RA-ILD merits further investigation. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  anti-CCP; autoantibodies; pulmonary fibrosis; rheumatoid arthritis; smoking

Mesh:

Substances:

Year:  2020        PMID: 32156708     DOI: 10.1136/annrheumdis-2019-216709

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

Review 1.  Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.

Authors:  Alesandra Florescu; Florin Liviu Gherghina; Anca Emanuela Mușetescu; Vlad Pădureanu; Anca Roșu; Mirela Marinela Florescu; Cristina Criveanu; Lucian-Mihai Florescu; Anca Bobircă
Journal:  Biomedicines       Date:  2022-06-09

2.  Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis-related interstitial lung disease: a meta-analysis.

Authors:  Sisi Xie; Shu Li; Bilin Chen; Qing Zhu; Lichang Xu; Fen Li
Journal:  Clin Rheumatol       Date:  2021-06-29       Impact factor: 2.980

3.  Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment.

Authors:  Sicong Huang; Vanessa L Kronzer; Paul F Dellaripa; Kevin D Deane; Marcy B Bolster; Vivek Nagaraja; Dinesh Khanna; Tracy J Doyle; Jeffrey A Sparks
Journal:  Curr Treatm Opt Rheumatol       Date:  2020-09-01

4.  Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies.

Authors:  Cristina Regueiro; Laura Nuño; Ana Triguero-Martinez; Ana M Ortiz; Alejandro Villalba; María Dolores Bóveda; Ana Martínez-Feito; Carmen Conde; Alejandro Balsa; Isidoro González-Alvaro; Antonio Gonzalez
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

5.  Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis.

Authors:  Raul Castellanos-Moreira; Sebastian C Rodriguez-Garcia; Sonia Cabrera-Villalba; María José Gomara; Georgina Salvador; Virginia Ruiz-Esquide; Julio Ramirez; Jose Inciarte-Mundo; Rosa Morla; Cristina Garcia-Moreno; Andrea Cuervo; Jose A Gómez-Puerta; Juan D Cañete; Isabel Haro; Raimon Sanmarti
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-10       Impact factor: 5.346

6.  Serum rheumatoid factor IgA, anti-citrullinated peptide antibodies with secretory components, and anti-carbamylated protein antibodies associate with interstitial lung disease in rheumatoid arthritis.

Authors:  Shomi Oka; Takashi Higuchi; Hiroshi Furukawa; Kota Shimada; Akira Okamoto; Atsushi Hashimoto; Akiko Komiya; Koichiro Saisho; Norie Yoshikawa; Masao Katayama; Toshihiro Matsui; Naoshi Fukui; Kiyoshi Migita; Shigeto Tohma
Journal:  BMC Musculoskelet Disord       Date:  2022-01-13       Impact factor: 2.362

Review 7.  Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings.

Authors:  Maria V Sokolova; Georg Schett; Ulrike Steffen
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-08       Impact factor: 10.817

Review 8.  Interstitial lung disease throughout the rheumatoid arthritis disease course.

Authors:  Gregory C McDermott; Tracy J Doyle; Jeffrey A Sparks
Journal:  Curr Opin Rheumatol       Date:  2021-05-01       Impact factor: 5.006

9.  The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients.

Authors:  Bogdan Kolarz; Marek Ciesla; Ann K Rosenthal; Magdalena Dryglewska; Maria Majdan
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-02-11       Impact factor: 5.346

10.  Peptides Bearing Multiple Post-Translational Modifications as Antigenic Targets for Severe Rheumatoid Arthritis Patients.

Authors:  Cristina García-Moreno; María J Gómara; Raúl Castellanos-Moreira; Raimon Sanmartí; Isabel Haro
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.